Quality and learning management + Vendor management and governance = 2x stronger together

Audit Ready or Audit Scramble?

Vendor Oversight Gaps to Address Before an Inspection

Outsourcing clinical work to a CRO, central lab, or Interactive Response Technology (IRT) vendor does not outsource your regulatory obligations. Regulators treat vendors as extensions of the sponsor organization. In most inspection findings, the root cause is not a single underperforming vendor but fragmented oversight: qualification records, performance data, and quality agreements dispersed across systems that were never designed to connect. The following four gaps are worth closing before that question is asked.

1. The Project Plan Exists. Nobody Follows It.

Most CRO relationships begin well. A scope of work and a project plan are put in place, along with a quality agreement that assigns clear responsibility for deviations, investigations, and change control. The difficulty is that none of these documents are revisited afterward. The project plan sits in a folder. Small deviations accumulate. Scope quietly expands. By the time anyone notices, the distance between what was agreed and what is actually happening has widened enough for an auditor to walk straight through it.

Sound familiar? A CRO's quality agreement clearly assigns deviation and Corrective and Preventive Action (CAPA) responsibilities on paper. Six months into the study, a late safety report surfaces, and three separate people each assume someone else was tracking it.

Proactive Actions:

• Separate business (master services agreement) and quality responsibilities (quality agreement) into dedicated agreements, with named owners for deviations, investigations, safety communication, and change control.
  ‍
• Review, on a regular cadence, whether documented responsibilities still match actual practice.
  ‍
• Document and file a new agreement whenever the vendor's scope or personnel changes.

Key takeaway: A project plan nobody revisits is just a piece of paper.A review cadence is what catches drift before it becomes a finding.

2. Your Vendor Was Qualified Three Years Ago. That's It.

Vendor qualification tends to receive more attention during selection: a questionnaire is completed, an audit may take place, and then the file goes quiet. Three years later, the vendor's team has turned over, their quality system has evolved, the company may have been acquired, and the qualification file still reflects only the original assessment. Recent FDA warning letters have required companies to overhaul their supplier qualification programs, including the criteria used for selection, qualification, and disqualification. The message is unambiguous: qualifying a vendor once and moving on does not constitute a vendor management program.

Sound familiar? A CRO's lead bio statistician has left, data management has been subcontracted, and the vendor has received two GCP findings on another sponsor’s study none of which appear in the qualification file.

Proactive Actions:

• Establish a risk-based requalification cadence, triggered by personnel changes, ownership changes, quality events, subcontracting changes, or GCP findings.
  ‍
• Request and maintain qualification evidence, inspection records, and corrective actions on an annual basis.
  ‍
• Treat qualification as a living lifecycle rather than a point-in-time checkbox.

Key takeaway: If a vendor file cannot show what changed and what was done about it, it is not a file it is a snapshot. A snapshot in an insufficient proof of oversight.

3. Vendor Performance Only Comes Up When Something Breaks.

Vendor performance is often managed reactively. A late deliverable is escalated. A deviation triggers a call. Each issue is addressed individually, but no one steps back to examine the pattern across them. There is no consolidated view, no structured review forum, and no documented record of the decisions made about the relationship.

This is precisely where the quarterly business review earns its place: a recurring, structured conversation that brings quality, CAPAs, deviations, and operational performance into a single view. Without it, isolated problems get resolved while trends go undetected until an inspector asks for the evidence.

Sound familiar? Three late monitoring visit reports, two overdue CAPAs, and an unreported protocol deviation occur within a single quarter, each handled on its own. No dashboard shows the pattern. When an inspector asks how vendor performance is monitored, the process is described and then the inspector asks to see the records.

Proactive Actions:

• Define performance metrics aligned to each vendor's scope, including but not limited to visit report timeliness, query resolution, CAPA closure, and deviation rates. Review them on a cadence proportional to vendor criticality.
  ‍
• Use a consistent agenda covering quality and operations together, and document the decisions reached, not just the discussion.
  ‍
• Escalate recurring issues through the quality process, not only through the project team.‍

Key takeaway: When vendor performance only comes up once something breaks, that is theopposite of oversight.

4. Your Vendor Changed Something. You Found Out Late.

Vendors swap subcontractors, update SOPs, rotate project teams, and change systems. These changes can affect the quality of the work performed on a sponsor's behalf and the state of vendor qualification. A quality agreement may require notification, but without a defined process for how that notification happens, what triggers it, and how the sponsor assesses its impact, changes are absorbed without ever being evaluated for their effect on the study.

Sound familiar? A CRO switches its clinical trial management system (CTMS) platform mid-study and mentions the change in passing on a project call. It is never routed through change control. Three months later, an auditor asks about the system change, and there is no documented assessment, no approval, and no notification record.

Proactive Actions:

• Define change-notification responsibilities in the quality agreement across specific categories: personnel, systems, subcontractors, SOPs, and facilities.
  ‍
• Establish which changes require notification only, which require assessment, and which require approval before implementation.
  ‍
• Maintain a traceable record of what changed, when notification was received, and what was decided.‍

Key takeaway: A change that was never assessed is indistinguishable from a change thatwas never known about. Both look identical in an inspection.

The Common Thread

The root cause underlying all four gaps is the same: oversight evidence is fragmented, oversight responsibilities lack clear ownership and evidence of oversight is tracked inconsistently. A lean clinical operations team does not need more documents or more head count. It needs qualification, performance, agreement, change, audit, and CAPA records for each vendor consolidated into one traceable lifecycle available on demand, rather than reconstructed under pressure.

AuraGxP's AuraTrace platform brings vendor qualification, oversight, supplier lifecycle management, CAPA, deviation, change control, and document management into one connected system. If vendor oversight evidence is currently scattered in more locations than can be counted on one hand, that is the gap worth closing first.

‍

When a Full-Time Quality Hire is Too Early, But Compliance Risk is Not

Somewhere between “we just dosed our first patient” and “we’re building out a commercial quality organization,” most biotech startups pass through an uncomfortable middle stretch.
‍
There’s no clean rulebook, no headcount trigger, no line in a board deck that says “hire your VP of Quality now.”
‍
What there is, instead, is a slow accumulation of risk: undocumented deviations, informal vendor oversight, training records living in someone’s inbox, and a growing awareness that if an auditor or an FDA inspector walked in tomorrow, the story wouldn’t hold together.

This is the gap fractional QA support exists to close.

The Compliance Risk Doesn’t Wait for Your Hiring Plan

It’s tempting to treat Quality as a “later” problem something to build once there’s a commercial product, a bigger team, and a bigger budget.
‍
But regulatory exposure doesn’t wait for Series B. It starts the moment a clinical program, a manufacturing partner, or a lab process exists.

The numbers back this up:

• FDA’s broader FY2024 data shows that approximately one in five clinical investigator inspections and one in six sponsor/CRO inspections resulted in VAI or OAI classifications. The recurring findings, weak monitoring, protocol deviations, incomplete records, and safety-reporting gaps are precisely the risks that emerge when clinical activity and outsourcing grow faster than quality oversight. Fractional QA helps lean biotechs close that gap before it becomes an inspection or diligence issue.

• ClinicalTrials.gov surpassed 500,000 registered studies in 2024, a milestone reached 25 years after the registry launched with just over 1,000 studies. That scale reflects how the scale of clinical activity and therefore compliance surface area has grown industry-wide, even as inspection scrutiny holds steady.
  ‍
• In FDA GCP-focused inspections, some of the most frequently cited deficiencies involve failure to follow the monitoring schedule, inadequate investigator oversight, and gaps in trial records and documentation exactly the kind of oversight gaps that show up when no one owns quality as a full-time function.
  ‍
• Recruiting-industry data on Series A through C clinical-stage companies shows Director- and VP-level Clinical Operations hiring growing 31% year-over-year and VP Regulatory Affairs hiring growing 22%, reflecting increasing operational demands as companies progress through IND-enabling and early clinical development.

Put those together and the picture is clear: compliance obligations start as soon as clinical or GMP activity begins even if the Quality organization scales up later. Full Quality leadership, in most cases, does not arrive nearly that early.

Did You Know?

Only about 0.3% of FDA GCP inspections result in an Official Action Indicated(OAI) classification the tier warning letters come from.

But that doesn’t mean the other 99.7% are risk-free: most VAI-classified inspections still require a documented remediation response, and unaddressed findings compound over time.

Why a Full-Time Quality Hire is Often Premature

A senior QA hire is a significant, ongoing burn-rate commitment: salary, benefits, ramp time, and the organizational weight of standing up a function from scratch.
‍
For a company still validating its clinical or manufacturing strategy, that’s often capital better spent elsewhere. There’s also a structural mismatch.
‍
Early-stage programs don’t need a fully built QMS on day one they need the right amount of Quality infrastructure for where they actually are: enough to be inspection-ready and defensible, not so much that it becomes bureaucratic overhead the team can’t sustain.

‍
Bringing on a full-time quality leader before there’s a stable base of clinical or manufacturing activity to manage often means paying for capacity the organization isn’t yet positioned to use and QA professionals who join too early can find themselves without the infrastructure, budget, or organizational buy-in to do the job they were hired for.

Meanwhile, the risk of doing nothing compounds quietly: deviations pile up without a formal process, training records go untracked, vendor oversight is informal, and by the time a Phase 3 transition, an inspection, or a partnership diligence request arrives, the gaps are no longer small.

‍
Industry observers of Quality-system build-outs note that expanding a QMS after the fact tends to demand a disproportionate burst of process mapping, documentation, and retraining work that’s far cheaper to do incrementally from the start than to backfill under deadline pressure.

What Fractional QA Actually Solves

Fractional or embedded QA support gives a growing biotech access to senior quality expertise without the fixed cost, ramp time, or premature organizational build-out of a full-time hire.
‍
Instead of a single generalist, the company gets targeted expertise exactly where it’s needed, scaled up or down as the program matures.

In practice, this looks like:

• Quality System Design & Implementation - building a QMS that’s fit-for-purpose for your current phase, not a scaled-down version of a commercial-stage system you don’t need yet.
  ‍
• Deviation, CAPA & Change Control Management - the operational core of staying inspection-ready, run consistently even without in-house headcount.
  ‍‍
• Document Control & Records Management - so SOPs, batch records, and quality documentation live in one traceable, audit-ready system instead of scattered folders.
  ‍‍
• Audit Management & Inspection Readiness Support - so the first time your quality system is stress-tested isn’t the day an inspector walks in.
  ‍‍
• Supplier Qualification & Vendor Oversight - extending the same rigor to your CROs and CDMOs that you apply internally.
  ‍‍
• Training Program Design & GxP Training - ensuring role-based training is assigned, tracked, and defensible, not assumed.

This is the model behind AuraGxP’s approach to Quality Management & Learning: helping life sciences organizations build phase-appropriate Quality systems that scale with the company, rather than forcing a choice between “no quality function” and “premature full-time hire.”

What This Looks Like With AuraGxP

AuraGxP’s Quality and Learning services are built specifically around this middle stretch the point where compliance risk is real, but a full internal Quality department isn’t yet justified.
‍
Rather than dropping in a generic playbook, the engagement is scoped to your current stage: deviation management, CAPA, change control, audit management, and inspection readiness support delivered as ongoing, embedded services, backed by the AuraTrace™ Quality & Training Platform for centralized documentation, automated training assignments, role-based learning paths, and real-time compliance visibility.

That combination expert oversight plus a platform that makes the work traceable is what allows fractional support to hold up under an actual inspection, not just look good on paper.

Signals You’re Ready for This Conversation

You don’t need a fully built organization to start thinking about quality infrastructure. Some common triggers:

• You’re preparing for your first IND-enabling studies or first-in-human trial.
  ‍
• You’ve engaged (or are about to engage) your first CRO, CDMO, central laboratory, or other GxP vendor.
  ‍
• You’re not sure if your current documentation, oversight, or quality processes can withstand an audit or regulatory inspection.
  

• You’re preparing for investor due diligence, a licensing agreement, a merger or acquisition, or a strategic partnership where your Quality systems will be evaluated.
  ‍
• You’re implementing an electronic Quality Management System (eQMS), document management system, or learning management system and need someone who understands both quality and system implementation.
  ‍
• You’ve had informal signs of quality drift, inconsistent documentation, ad-hoc vendor communication, undocumented decisions, or missing training records and recognize that these small issues could become larger compliance risks as the company grows.
  ‍
• Training is inconsistent, difficult to track, or lacks documented evidence that employees have been trained on current procedures.
  ‍
• Deviations, CAPAs, change controls, or risk assessments are being handled inconsistently or not at all.

None of these require a full-time VP of Quality. All of them require someone accountable for Quality who knows what “inspection-ready” actually looks like.

Frequently Asked Questions

When should a biotech startup bring on fractional QA?
‍
Most companies benefit from starting before their first IND-enabling study, first CRO/CDMO engagement, or first outside diligence process not after a documentation gap has already surfaced.

Is fractional QA the same as hiring a consultant for a single project?
‍
Not quite. Fractional QA is ongoing and embedded covering deviation management, CAPA, training, and vendor oversight continuously rather than a fixed-scope project engagement.

Does fractional QA replace the need for a full-time quality hire eventually?
‍
Not necessarily. Fractional QA can bridge the gap before a full-time hire, complement an existing quality team, or provide specialized expertise as needs evolve. Even after an internal hire is made, fractional support can add execution capacity for a VP of Quality—or provide fractional leadership when the company’s budget currently supports only a junior quality hire.

The Bottom Line

The choice isn’t between “hire a quality leader” and “hope for the best.”

Fractional QA support exists precisely because compliance obligations start earlier than most organizations are staffed to handle them and because building a right-sized, phase-appropriate quality system now is far cheaper than remediating a gap later, whether that gap surfaces in an FDA inspection, a partner’s due diligence, or a deviation that should have been caught months earlier.

AuraGxP helps growing life sciences organizations build and scale exactly this kind of quality function inspection-ready from day one, without asking you to over-invest before you’re ready to do so.

If you’re weighing whether your compliance risk has outgrown your current quality resourcing, that’s a conversation worth having now, not after your next inspection.

Want to talk to AuraGxP about phase-appropriate QA support?
‍
Mail us at hello@auragxp.com

About the Author:

Diana I. Shea is a Quality Leader and consultant with over 20 years of experience in the pharmaceutical and biotechnology industries.  

She specializes in building and scaling phase-appropriate Quality Management Systems (QMS), GxP Quality programs, and inspection readiness initiatives for emerging and growth-stage organizations. Diana has led Quality Operations functions including Document Control, Training, and Quality Systems, while implementing compliant digital platforms that improve operational efficiency, inspection preparedness, and quality culture.